Pricing Log in Create free account
Friday 6 November 2026 Export GRAL’s income statement to Excel — free account

GRAIL, Inc.

GRAL Healthcare Diagnostics & Research

GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.

Revenue
+3.71%
EPS
+10.2%
Free cash flow
−24.9%

Quarter to September 2026, against a year earlier

124.40 19.26 −13.41%
Market cap
$5.3B
P/E
0.0×
Fwd P/E
−14.5×
Dividend yield
—
F-score
6/9
Altman Z
0.37
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

GRAIL, Inc. (GRAL) Revenue

Alert me on Revenue

GRAIL, Inc.'s revenue for fiscal 2025 was $147.2M, up 17.2% from $125.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $166.6M. Revenue has risen for 3 consecutive fiscal years. GRAIL, Inc. ranks 30th of 47 Diagnostics & Research companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $147.2M 17.18%
FY2024 $125.6M 34.90%
FY2023 $93.1M 67.61%
FY2022 $55.6M —

Quarterly newest first

Period Revenue Change
Sep 2026 $37.5M (16.00%)
Jun 2026 $44.7M 9.57%
Mar 2026 $40.8M (6.45%)
Dec 2025 $43.6M 20.45%
9 more quarters

Revenue against peers

Company Revenue
ICLR ICON PLC compare $8.2B
RDNT RadNet, Inc. compare $2.3B
QGEN QIAGEN N.V. compare $2.1B
SHC Sotera Health Company compare $1.2B
VCYT Veracyte, Inc. compare $581.8M
CDNA CareDx, Inc. compare $497.4M
BLLN BillionToOne, Inc. compare $436.9M
ADPT Adaptive Biotechnologies Corporation compare $298.0M
GRAL GRAIL, Inc. $166.6M

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on GRAL